Endobronchial Ultrasound Biopsy Market Size, Share & Trends Analysis Report By Product (EBUS Scopes, EBUS Needles), By Procedures (EBUS-Transbronchial, Needle Aspiration), By End-use, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global endobronchial ultrasound biopsy market size was estimated at USD 728.6 million in 2024 and is projected to grow at a CAGR of 4.83% from 2025 to 2030. This growth can be attributed to the rising prevalence of cancer, increasing technological advancements in endobronchial ultrasound (EBUS) technology, growing geriatric population, growing prevalence of respiratory diseases, and the increasing adoption of minimally invasive procedures. According to the WHO, the global elderly population aged 60 years and above is expected to increase from around 1.1 billion in 2021 to 1.4 billion in 2030.

The increasing prevalence of lung cancer drives the growth of endobronchial ultrasound biopsy market as it is one of the leading causes of cancer-related deaths worldwide, with rising incidence rates attributed to factors such as smoking, air pollution, and occupational hazards. For instance, the American Cancer Society projects that in 2025, there will be approximately 226,650 new lung cancer cases in the U.S., with 110,680 cases occurring in men and 115,970 in women. In addition, it is estimated that there will be around 124,730 deaths due to lung cancer, comprising 64,190 men and 60,540 women. As early and accurate diagnosis is critical for improving patient outcomes, there is a growing demand for minimally invasive procedures such as EBUS-guided biopsy. This technique allows for precise sampling of lymph nodes and lung lesions, allowing early-stage detection and staging of lung cancer.

Source: International Agency for Research on Cancer, GLOBOCAN, Grand View Research Analysis

Furthermore, the rising prevalence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD), tuberculosis, others, significantly contribute to the market growth. As these conditions become more widespread due to factors such as smoking, air pollution, and aging populations, the demand for minimally invasive diagnostic procedures has increased. In addition, advancements in EBUS technology, including better imaging resolution and real-time needle guidance, enhance diagnostic efficiency, are further increasing their adoption among healthcare providers.

Market Concentration & Characteristics

The industry growth stage is medium, and the pace of the market growth is accelerating. The market for endobronchial ultrasound biopsy is characterized by technological advancements, growing prevalence of cancer, aging population and increasing preference of minimally invasive procedures among patients and healthcare providers, which drives the demand of endobronchial ultrasound biopsy for conditions such as lung cancer, COPD and others.

The endobronchial ultrasound biopsy (EBUS) industry is witnessing significant innovation as market players introduce advanced products and accessories to meet the increasing demand for effective EBUS procedures and improving patient outcomes. For instance, in September 2023, Broncus Medical launched the BioStar Transbronchial Aspiration Needle (TBNA) for minimally invasive lung cancer diagnostics. It integrates with endobronchial ultrasound procedures, offering various gauge options and advanced design for reduced tissue disruption and improved accuracy.

The endobronchial ultrasound (EBUS) industry market is expected to witness significant partnership and collaboration activities from companies to enhance technological innovation and expand their market presence. Moreover, collaborations with healthcare providers also drive the adoption by promoting minimally invasive procedures for lung cancer and respiratory disease diagnosis.

Regulations play a critical role in shaping the endobronchial ultrasound biopsy industry influencing product approvals, market access, and adoption rates. Stringent regulatory requirements from agencies such as the FDA, EMA, and others ensure product safety and efficacy. Compliance with evolving guidelines related to medical device classification, clinical trial requirements, and post-market surveillance is essential for market entry and expansion. However, excessive regulatory burdens can limit competition, potentially driving up costs for healthcare providers.

Traditional diagnostic methods such as conventional bronchoscopy, Transthoracic Needle Aspiration (TTNA), and surgical biopsy serve as potential substitutes for the endobronchial ultrasound biopsy industry. While TTNA offers direct access to peripheral lung lesions, it carries a higher risk of pneumothorax. Similarly, surgical biopsy, including mediastinoscopy, provides a definitive diagnosis but is invasive, costly, and associated with longer recovery times. However, EBUS-guided biopsy combines real-time imaging with minimally invasive tissue sampling, reducing complications while improving diagnostic accuracy, which contributes to its increasing demand.

The endobronchial ultrasound biopsy industry is witnessing growth across various regions, driven by increasing lung cancer prevalence, advancements in minimally invasive diagnostic techniques, and improved healthcare infrastructure. In addition, favorable regulatory approvals and strategic partnerships between global manufacturers and local distributors are accelerating market penetration. Moreover, market players are expanding their production capabilities in various regions to meet the increasing demand for these products. For instance, in October 2024, GE Healthcare announced the expansion of its production of medical imaging equipment in Waukesha County, Wisconsin, U.S., including MRI and ultrasound machines, to meet rising demand. The expansion aims to enhance healthcare delivery and innovation, responding to the growing need for advanced tools in hospitals and clinics worldwide.

Product Insights

The EBUS scopes segment dominated the market in 2024 with the largest revenue share of 33.0%, owing to the demand for minimally invasive diagnostic procedures for lung cancer and mediastinal lymphadenopathy. Moreover, technological innovations in EBUS scopes, such as high-frequency ultrasound probes, enhanced visualization, and improved needle design, are accelerating their adoption. For instance, in September 2024, FUJIFILM Healthcare Europe announced the ARIETTA 750 FF ENDO ultrasound system, compatible with various ultrasound endoscopes and bronchoscopes. It features advanced imaging technologies such as eFocusing and Detective Flow Imaging, enhancing diagnostic capabilities.

The EBUS needles segment is anticipated to witness the fastest growth over the forecast period. As healthcare providers prioritize early and accurate diagnosis, the demand for EBUS-guided transbronchial needle aspiration procedures is increasing. Technological advancements, including improved needle design for better sample collection and reduced patient discomfort, are further contributing to the segment growth. Market players are focusing on product innovations, such as flexible and fine-gauge needles, to enhance procedural efficiency and diagnostic capabilities.

Procedure Insights

The EBUS-Transbronchial Needle Aspiration (EBUS-TBNA) segment captured the largest revenue share of 61.1% in 2024. Clinicians and healthcare providers have shifted toward EBUS-TBNA due to its higher diagnostic yield, reduced patient discomfort, and lower complication rates compared to conventional mediastinoscopy. In addition, growing preference for ambulatory and outpatient procedures is also driving demand, as EBUS-TBNA allows same-day discharge, improving hospital efficiency and cost-effectiveness.

The EBUS-guided biopsy segment is expected to grow at a fastest CAGR of 5.26% during the forecast period. Advancements in minimally invasive techniques have made EBUS-guided biopsy as a preferred alternative to traditional mediastinoscopy, reducing patient risk and hospital stay. Healthcare providers prefer this procedure owing to its better diagnostic outcomes and safety, driving its adoption in hospitals and specialized diagnostic centres. Moreover, expanding applications beyond oncology, including infectious and inflammatory disease diagnoses, are further contributing to its increasing preference in the healthcare facilities.

End use Insights

The hospitals segment accounted for the largest revenue share of 42.2% in 2024. Hospitals prioritize EBUS technology due to its high diagnostic accuracy and reduced patient risk compared to traditional biopsy methods. The integration of advanced imaging and robotic-assisted bronchoscopy is further enhancing procedural efficiency. In addition, hospitals benefit from favorable reimbursement policies and government funding for advanced diagnostic technologies, making them the primary adopters of EBUS biopsy systems.

The ambulatory surgical centers segment is expected to witness the fastest growth over the forecast period. Ambulatory surgical centers offer a lower-cost alternative to hospitals while maintaining high procedural efficiency, making them an attractive option for both patients and payers. Advancements in portable ultrasound technology and improved reimbursement policies for outpatient settings have enabled these facilities to integrate EBUS procedures.

Regional Insights

The endobronchial ultrasound biopsy market in North America dominated the global market and accounted for a revenue share of 29.18% in 2024, owing to the increasing prevalence of respiratory diseases, such as lung cancer, and the rising demand for minimally invasive diagnostic techniques. For instance, according to the Canadian Cancer Society, lung cancer accounts for approximately 25% of all cancer deaths in Canada, making it the leading cause of cancer mortality in the country. In 2023, over 31,000 Canadians were anticipated to be diagnosed with lung cancer, with around 20,000 projected deaths. The adoption of EBUS procedures in the region is also driven by advancements in medical technologies that offer improved accuracy and safety over traditional methods.

U.S. Endobronchial Ultrasound Biopsy Market Trends

The growth of the endobronchial ultrasound biopsy market in the U.S. is being driven by the increasing prevalence of respiratory diseases, which are one of the leading causes of death in the country. According to the Centers for Disease Control and Prevention (CDC), around 4.3% of adults aged 18 and over were estimated to be living with COPD, emphysema, or chronic bronchitis in 2023. As more patients seek early diagnosis and treatment, the demand for minimally invasive procedures such as EBUS is expected to witness growth over the forecast period.

Below chart indicates the estimated prevalence of COPD across U.S. states in 2024:

Source: Grand View Research Analysis

Source: Grand View Research Analysis

Europe Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in Europe is driven by the rising incidence of lung cancer and the increasing demand for early and accurate diagnostic tools. European countries with well-established healthcare systems such as Germany, France, and the UK are adopting EBUS due to its ability to deliver precise, minimally invasive biopsies for diagnosing lung cancers and other pulmonary diseases. The ability to perform biopsies of the lung, coupled with improved patient outcomes such as faster recovery times and reduced complications, has significantly contributed to the adoption of EBUS technologies.

The endobronchial ultrasound biopsy market in the UK has witnessed significant growth, fueled by the country’s strong emphasis on early detection and accurate diagnosis of lung diseases. The National Health Service (NHS) has prioritized the implementation of advanced diagnostic techniques, including EBUS, as part of its drive to improve patient outcomes and reduce mortality rates. Moreover, the integration of EBUS with other diagnostic methods, such as positron emission tomography (PET) and computed tomography (CT), is enhancing the overall effectiveness of lung cancer diagnostics in the UK.

Germany has witnessed significant growth in the endobronchial ultrasound biopsy market, driven by its advanced healthcare infrastructure and a growing focus on precision medicine. The country is witnessing a rising prevalence of respiratory diseases, which has increased the demand for minimally invasive diagnostic tools such as EBUS.

Asia Pacific Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in Asia Pacific is anticipated to witness the fastest growth at a CAGR of 5.49% from 2025 to 2030 owing to the increasing burden of respiratory diseases, developing healthcare infrastructure, increasing healthcare access and the growing adoption of advanced medical technologies. Countries such as Japan, China, and India are at the forefront of this expansion, with rising healthcare awareness and a focus on improving diagnostic capabilities.

The endobronchial ultrasound biopsy market in Japan is driven by the country’s advanced healthcare system, aging population, and rising focus on early diagnosis and precision medicine. Japan has one of the highest rates of lung cancer in the world, which has increased the adoption of advanced tools such as EBUS. For instance, according to the World Cancer Research Fund, Japan had around 136,723 new lung cancer cases in 2022, which was 3rd globally after the U.S. and China.

The endobronchial ultrasound biopsy market in China is driven by the rising incidence of lung cancer and the country's ongoing healthcare modernization efforts. China's healthcare system is significantly evolving, with increased investments in medical technology and infrastructure. The government has also made efforts to improve the accessibility of advanced medical procedures, encouraging the widespread use of diagnostic tools such as EBUS. As more hospitals and medical centers across China integrate EBUS into their lung cancer treatment procedures, the market for endobronchial ultrasound biopsy in China is expected to witness growth over the forecast period.

Latin America Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in Latin America is driven by the increasing prevalence of lung cancer and the demand for more advanced diagnostic solutions across the region. Healthcare systems in Latin America are increasingly focused on reducing the costs associated with invasive surgeries and lengthy hospital stays, indicating EBUS as a cost-effective solution. The combination of rising cancer rates, the adoption of advanced medical technologies, and a growing emphasis on early and accurate diagnosis is expected to drive the market growth over the forecast period.

The endobronchial ultrasound biopsy market in Brazil is driven by increasing healthcare access, development of healthcare infrastructure, and a rising demand for advanced diagnostic technologies. Brazil's healthcare system has been increasingly investing in advanced medical technologies, with a focus on improving the quality of diagnostic procedures while reducing the need for more invasive and costly surgeries. With ongoing improvements in Brazil’s healthcare infrastructure and a growing awareness of the importance of early diagnosis, the market for endobronchial ultrasound biopsy in Brazil is expected to witness growth.

MEA Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in the MEA is witnessing significant growth, driven by an increasing focus on improving healthcare infrastructure, the rising prevalence of respiratory diseases, and the adoption of advanced diagnostic technologies in the region’s healthcare sector.

The endobronchial ultrasound biopsy market in Saudi Arabia is experiencing notable growth, driven by the country’s healthcare infrastructure developments and the increasing burden of respiratory diseases. Saudi Arabia’s healthcare sector has made significant investments in advanced diagnostic technologies as part of the Vision 2030 initiative, which aims to enhance the quality of healthcare services and improve patient outcomes, which is also expected to fuel the market growth over the forecast period.

Key Endobronchial Ultrasound Biopsy Company Insights

Key players operating in the endobronchial ultrasound biopsy market are undertaking various initiatives to strengthen their market presence and increase the reach of their products. Strategies such as product launches, partnerships, expansion are playing a key role in driving market growth.

Recent Developments

• In September 2024, FUJIFILM Healthcare Europe GmbH announced the compatibility of its ARIETTA 750 FF ENDO ultrasound system with several ultrasound endoscopes and a linear bronchoscope. This system features advanced technologies such as “eFocusing” for improved image clarity and “Carving Imaging” for enhanced visualization.

• In October 2023, Praxis received FDA clearance for its EndoCore EBUS-TBNA biopsy device, designed to enhance the accuracy and efficiency of lung biopsies. This innovative device aims to improve patient outcomes by allowing better tissue sampling during endobronchial ultrasound procedures.

Endobronchial Ultrasound Biopsy Market Report Scope

Global Endobronchial Ultrasound Biopsy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global endobronchial ultrasound biopsy market report based on product, procedures, end use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • EBUS Scopes

  • EBUS Needles

  • Ultrasound Processors & Imaging Systems

  • Accessories

• Procedure Outlook (Revenue, USD Million, 2018 - 2030)

  • EBUS-Transbronchial Needle Aspiration (EBUS-TBNA)

  • EBUS-Guided Biopsy

• End use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Ambulatory Surgical Centers (ASCs)

  • Specialty Clinics

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait